Dr. Stuart W. Titus, Ph.D. and CEO of Medical Marijuana, Inc. has made some exciting announcements about the future of his company. Medical Marijuana, Inc., traded publicly under the ticker symbol MJNA, has led the way in terms of improving accessibility to medical marijuana as a treatment for serious neurological diseases and disorders such as multiple sclerosis and epilepsy. The Company produces a line of cannabinoid products that have changed the legislation in multiple Latin American countries, as improved regulation of these products has made life-changing treatment available to pediatric and adult patients who suffer from debilitating chronic conditions. While great progress has been made, Dr. Titus warns that there is still work to be done.
The Difference Between Hemp and Marijuana
It is essential to clarify the issues that hinder governments from approving medical marijuana treatments that have been scientifically proven. MJNA has poured a significant amount of time and funding into testing and development to make sure that its products are of the highest quality and effectiveness. While marijuana and hemp belong to the same family, the products produced from them are significantly different.
Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the two most prominent cannabinoid molecules found in cannabis. Cannabinoids are compounds that are unique to Cannabis – the plant genus that includes both hemp and marijuana. There are over eighty different cannabinoids, but THC and CBD are the best understood and most studied. THC is a psychotropic compound that produces the “high” people think of when they think of marijuana.
CBD and THC exist in cannabis plants in a wide range of proportions. Some cannabis has far more THC than CBD; this is commonly called “marijuana.” Marijuana is cannabis that has been cultivated, manipulated and/or cloned by man over many decades for its intoxicating effects. Typical THC content in marijuana, including “medical” marijuana, ranges from 3% all the way up to 30%, with the average between 11%-13%. Hemp is just the opposite; it has negligible THC (generally less than 0.3%) and an abundance of CBD.
Unlike opioids and other drugs that alter the patient’s state of mind, hemp reduces seizures and other symptoms without inducing an altered state. Most pharmaceuticals treat only the synapses, while cannabinoids treat a larger range of neurological activity.
Proven Treatment Success
In 2014, Katiele Fischer was granted permission from the Brazilian government to import MJNA products for her daughter, Amy. Born with a seizure disorder, Amy went from having 40 seizures each day to going months without an episode. This incredible change occurred over a 60-day period, which allowed her to interact with and relate to her family in a way her illness previously made impossible.
The benefits of CBD in patients with neurological disorders have been made obvious through extensive testing and case studies. The Brazilian government now offers subsidized medical marijuana treatment for people with symptoms like young Amy’s. Without the support of the Brazilian government, many families were forced to seek treatment through illegal means. Legal importation allows more families to access these affordable and life-changing treatment methods. Because CBD does not cause psychotropic effects, it allows patients to resume their normal quality of life while experiencing a reduction in pain and other debilitating neurological conditions.
Controlled results are another reason why the legalization of medical marijuana is so important. Families who attempt to grow their own medical marijuana because importation is illegal could unintentionally create medical issues for their loved ones. Home production does not usually produce a sufficient level of CBD for treatment. THC is also present in home-grown strains, so it is essential to work with products that have been created in a laboratory to yield specific results.
While the battle to legalize medical marijuana in Brazil was a success, there is still a war to be waged on unfair legislation. Patients and families deserve the quality of life that these revolutionary products can bring, and all patients should have the right to access medical marijuana and hemp treatments in a safe and legal manner. MJNA creates all of its products in a controlled laboratory setting for consistent results and quality of product. Many doctors have come alongside MJNA and the families of the patients it has helped to encourage governments in their home countries to loosen their restrictions on medical marijuana.
Stigma has led to resistance in many communities around the world when it comes to legalizing hemp products. However, the stories of how products like Real Scientific Hemp Oil™ (RSHO™) have changed lives like Amy Fischer’s are changing the perception of medical marijuana. Add to this the international opioid crisis, and it is easy to see why so many patients and physicians alike are seeking the non-addictive and safe treatment options hemp-based products provide.
About the Author
Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/